文献速递癫痫

新诊断癫痫患者抗癫痫药物启动、更换或终止的趋势:一项全国性研究

Trends in Antiseizure Medication Initiation, Switch, or Termination in Patients With Newly Diagnosed Epilepsy: A Nationwide Study.
PubMed 文献 · Neurology · 2024-06-13

该全国性研究基于瑞典患者登记和处方药登记,纳入2010-2022年新诊断癫痫患者67,984例(平均年龄46岁,46%女性),其中66,441例以单药治疗启动。左乙拉西坦启动比例从2010年10%升至2022年55%,丙戊酸从10%降至5%;5年内31%-47%患者更换单药,20%-42%终止治疗。

要点

  • 左乙拉西坦和拉莫三嗪是最常起始的抗癫痫药物。
  • 左乙拉西坦起始比例从2010年10%升至2022年55%。
  • 5年内31%-47%患者更换单药,20%-42%终止治疗。

核心结论

  • 左乙拉西坦和拉莫三嗪是最常起始的抗癫痫药物,即使在合并症或合用药物使这些药物使用复杂化的患者中也是如此,这凸显了需要改进处方者关于根据个体患者特征选择抗癫痫药物的教育。
  • 医院内抗癫痫药物使用未在瑞典处方药登记中捕获。

研究设计与样本

  • 纳入2010-2022年瑞典患者登记中具有新发癫痫住院诊断且2010-2022年期间首次配发任何抗癫痫药物的患者(任何年龄),使用2000-2009年回顾性信息识别新发患者。
  • 共纳入67,984例患者,平均年龄46岁,46%为女性;其中66,441例以单药治疗启动抗癫痫药物。
  • 主要结局为按年龄、性别、合并症及合用抗抑郁药或避孕药划分的首次配发抗癫痫药物;次要结局为通过生存分析评估的抗癫痫药物更换或终止时间。

主要发现

  • 以单药治疗启动的相对风险在各年龄组、性别或合用抗抑郁药、避孕药或精神疾病患者之间无差异(相对风险和95%置信区间均包含1.0)。
  • 左乙拉西坦启动治疗的比例从2010年10%增至2022年55%;丙戊酸从10%降至5%。
  • 起始5种最常用抗癫痫药物之一的可能性在所有比较组间均存在差异(0.3<相对风险<1;95%置信区间<1;1<相对风险<15;1<95%置信区间)。
  • 7%的育龄女性患者以丙戊酸启动治疗;精神疾病合并症患者中最常见的初始抗癫痫药物为左乙拉西坦(40.2%);使用避孕药的女性中最常处方的初始抗癫痫药物为拉莫三嗪(50.4%)。
  • 治疗终止可能性最高见于儿童(1.72<相对风险<3.07;1<95%置信区间)和精神疾病合并症患者(以卡马西平启动者相对风险1.38;1<95%置信区间;或以拉莫三嗪启动者相对风险1.31;1<95%置信区间)。

关键数值与推荐

  • 5年内31%至47%的患者从初始单药治疗更换为新的单药治疗。
  • 5年内20%至42%的患者终止抗癫痫药物治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 医院内抗癫痫药物使用未在瑞典处方药登记中捕获。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Few studies evaluate physicians' choice of antiseizure medication (ASM) to treat patients with newly diagnosed epilepsy. The objective of this study was to analyze the choice of ASM and its use by age, sex, psychiatric comorbidities, and concurrent treatment with other drugs (antidepressant medications and contraceptives) in patients who initiated epilepsy treatment using monotherapy. METHODS: Included in this study were persons (any age) with an incident hospital diagnosis of epilepsy during 2010-2022 in the Swedish Patient Register (SPR), preceding a first dispensing of any ASM (as reported in the Swedish Prescribed Drug Register, SPDR) for the period 2010-2022. Incident patients were identified using retrospective information during 2000-2009 in the SPR. Primary outcome was first dispensed ASM by age, sex, comorbidity, and comedication with antidepressants or contraceptives (SPDR). Secondary outcomes were time to ASM switch or termination assessed by survival analyses. RESULTS: Of 67,984 patients included (mean age 46; 46% female), 66,441 initiated ASM treatment using monotherapy. Relative risk (RR) for initiating treatment using monotherapy did not differ between age groups, sex, or patients with concurrent treatment with antidepressants, contraceptives, or psychiatric illness (RR and 95% CI did include 1.0). The share initiating treatment using levetiracetam increased from 10% in 2010 to 55% in 2022; valproic acid: 10%-5%. The likelihood of initiating treatment using 1 of the 5 most frequent ASMs differed between all compared groups (0.3 < RR < 1; 95% CI < 1; 1 < RR < 15; 1 <95% CI). Seven percent of female patients of childbearing age initiated treatment with valproic acid, levetiracetam was the most frequent initial ASM in patients with psychiatric comorbidity (40.2%), and lamotrigine the most prescribed initial ASM to women on contraceptives (50.4%). Highest likelihoods of treatment termination were found among children (1.72 < RR < 3.07; 1 <95% CI) and among patients with psychiatric comorbidity (initiated on carbamazepine, RR 1.38; 1 <95% CI or lamotrigine, RR 1.31; 1 <95% CI). Thirty-one percent to 47% of patients switched from an initial monotherapy to a new monotherapy within 5 years. Twenty percent to 42% terminated ASM treatment within 5 years. DISCUSSION: Levetiracetam and lamotrigine were the most frequently dispensed initial ASMs, also among patients with comorbidities or comedications complicating the use of these ASMs, highlighting the need for improved education of prescribers concerning ASM selection in relation to individual patient characteristics. Use of ASMs in hospital is not captured in the SPDR.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bolin K, Patric B, Tomson T, et al. Trends in Antiseizure Medication Initiation, Switch, or Termination in Patients With Newly Diagnosed Epilepsy: A Nationwide Study. Neurology. 2024. PMID: 38870473. doi:10.1212/WNL.0000000000209500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。